Antibody–drug conjugate (ADC) development has evolved greatly over the last 3 decades,
including the Food and Drug Administration (FDA) approval of several new drugs. However …

Poor tissue penetration remains a major challenge for antibody-based therapeutics of solid
tumors, but proper dosing can improve the tissue penetration and thus therapeutic efficacy of …

Over the last decade, the biopharmaceutical market has witnessed a new wave of
development in antibody–drug conjugates (ADCs) due to their high efficacy in cancer …

With the recent approval of 3 new antibody drug conjugates (ADCs) for solid tumors, this
class of drugs is gaining momentum for the targeted treatment of cancer. Despite significant …

After several notable clinical failures in early generations, antibody–drug conjugates (ADC)
have made significant gains with seven new FDA approvals within the last 3 years. These …

In preclinical models, the development and optimization of protein–drug conjugates require
accurate determination of the plasma and tissue profiles of both the protein and its …

Polatuzumab vedotin (or POLIVY®), an antibody–drug conjugate (ADC) composed of a
polatuzumab monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a …

Understanding pharmacokinetics and biodistribution of antibody–drug conjugates (ADCs) is
a one of the critical steps enabling their successful development and optimization. Their …

Intratumoral heterogeneity is a leading cause of treatment failure resulting in tumor
recurrence. For the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) …

Cysteine cathepsins are important proteases that play important roles in physiological and
pathological processes and have the potential to be target candidates for disease diagnosis …